Scheduler and Processor of the Episode Processor of the Control of				
Process				
Production Pro	Technology appraisal (TA)	-	Adhere	nce of local formulary to NICE
1000-1-100			indication Yes OR	Reason provided if "No"
Section Sect	2021-22			
2001 1.000		30/03/2022	No	Terminated appraisal
12.77. Production for the control of control	$\underline{\text{TA781-Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell}}$	30/03/2022	Yes	
The continues the meanth through the control beard and provided in the continues of the control		24/03/2022		
MONOTODE NO CONTROLLED		16/03/2022	No	
1277. Experimental continues deligness deligne		09/03/2022		Not applicable to CWFT -
Annual Control of Cont		09/03/2022		
TAZES - Designation for entires (more labeled actions of the prepared of a protection of the prepared of the protection	TA776 - Pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive	09/03/2022		
TATE. Literations to two pages or artistation, Maries Cell improved. 1.1777 Literations for recent a photon hand failure of the control of t		09/03/2022	-	Notrecommended
TATES Empathbor for thorse yellowers board faultre with modern direction in the Company of the C		09/03/2022		Terminated appraical
10.72 Forestern under the require uniqued or effective dissolation requires and incomplete and i	-	09/03/2022	-	Terrimitated approisar
ADVICE Position and Conference of Conference		23/02/2022		
14707. Percentage and after under control and sections of the control and sections of		09/02/2022		Torminated apprairal
A March Delivers for mostery against activities of the complete and company against the Company of the Company	TA770 - Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-			i erminateo appraisai
TABLE - Institution for adjust an treatment of control by the second second and control by the second second second and control by the second se				Not applicable to CWFT -
ALTAS - Foundation for the partie active product in the partie active product in the parties of				Condition not treated at CWH and WMUH site
1A/16. Problemplands or all control transmits and inclinate inclin				
TACKS - Productional to death of a treatment control and a treatment control and a treatment of the control and a treatment				
A Continue to the control of the con				
Anise - substitution for continuous continuous continuous attention is sterriffed. Oz/02/2022 Yes	chemotherapy is unsuitable			
Language is suitable				
AVS - Sementini for advant treatment of CFF mustines assessment assessment of CFF mustines assessment assessment of CFF mustines assessment assessment assessment assessment assessment assessment of CFF mustines assessment as	transplant is suitable		Yes	
TAT50 - Sejecration for treating rest Eff. Each operation in must eff. Each operation in marked Eff. Each operation in Eff. Each o	<u>after chemotherapy</u>		No	Terminated appraisal
TA755 - Footsmarkins for treating refreshing	cancer after complete tumour resection		Yes	
TA758 - Soliminetal for treating excesses daytime sheepines caused by narrodepay TA757 - Calotescravir with rijovirine for treating steps. TA758 - Redatable for treating disease enlated spenometals or symptoms in myelofibroots. TA758 - Redatable for treating disease enlated spenometals or symptoms in myelofibroots. TA758 - Redatable for treating disease enlated spenometals or symptoms in myelofibroots. TA758 - Redatable for treating disease enlated spenometals or symptoms in myelofibroots. TA758 - Redatable for treating disease enlated spenometals or symptoms in myelofibroots. TA759 - Redatable for treating disease enlated spenometals or symptoms. TA759 - Calouenbarnable for treating active autoantibody-positive systemic lupus enythematosus. TA759 - Calouenbarnable for treating active autoantibody-positive systemic lupus enythematosus. TA759 - Oligands for mainternance treatment of BRCA mutation positive metastatic pararesis. TA759 - Oligands for mainternance treatment of BRCA mutation positive metastatic pararesis. TA759 - Oligands for mainternance treatment of BRCA mutation positive metastatic pararesis. TA759 - Unapatic for mainternance treatment of BRCA mutation positive metastatic pararesis. TA759 - Unapatic for mainternance treatment of preceded positive myeloric disorders. TA759 - Unapatic for treating the symptoms of myotosia in non-dystroohic myeloric disorders. TA759 - Newbornable for advanced treatment of resected occorbinated accordances. TA759 - Newbornable for advanced treatment of resected occorbinated accordances. TA759 - Newbornable for advanced treatment of resected occorbinated accordances. TA759 - Newbornable for advanced treatment of resected occorbinated accordances. TA759 - Newbornable for advanced treatment of resected occorbinated accordances. TA759 - Newbornable for advanced treatment of res	cancer		Yes	
TA757 - Cabbineravir with injovine for treating HIV-1 TA756 - Federatinis for treating disease-related splenomespally or symptoms in myelofilarosis TA756 - Bederatinis for treating disease-related splenomespally or symptoms in myelofilarosis TA756 - Bederatinis for treating disease-related splenomespally or symptoms in myelofilarosis TA756 - Bederatinis for treating disease-related splenomespally or symptoms in myelofilarosis TA756 - Bederatinis for treating splenal muscular attropity 15/12/2021 No Condition not treated at CWH and WMUH after TA754 - Monamulitamab for previously treating focal onset seriouses in epilepsy 15/12/2021 Yes TA753 - Carobismate for treating focal onset seriouses in epilepsy 15/12/2021 Yes TA753 - Displanomab for treating active autoamibody-positive systemic lugus enythematous. 15/12/2021 No Condition not treated at CWH and WMUH site. TA754 - Displanomab for treating severe authors with type 2 inflammation 08/12/2021 No Condition not treated at CWH and WMUH site. TA755 - Displanomab for treating severe authors with type 2 inflammation 08/12/2021 No Condition not treated at CWH and WMUH site. TA756 - Displanomab for treating severe authors with type 2 inflammation 08/12/2021 No Condition not treated at CWH and WMUH site. TA756 - Displanomab for treating the symptoms of my optional in non-dystrophic myelonic disorders. 16/12/2021 No Terminated appraisal 25/01/2022 No Terminated appraisal 16/12/2021 No Condition not treated at CWH and WMUH site. TA746 - Newborks of my optional in non-dystrophic myelonic disorders. 17/12/2021 No Condition not treated at CWH and WMUH site. TA746 - Newborks of my optional in non-dystrophic myelonic disorders. 17/12/2021 No Condition not treated at CWH and WMUH site. TA746 - Newborks of my optional in non-dystrophic myelonic disorders. 17/12/2021 No Condition not treated at CWH and WMUH site. 17/12/20 No Condition not treated at CWH and WMUH site. 17/12/20 No Condition not treated at CWH and WMUH site. 17/12/20 No C			No	
TA756 - Fedraltinih for treating disease-related selenomean for symptoms in myelofiltorosis 16/12/2021 TA755 - Rigidiplem for treating sonal muscular atmorby. 16/12/2021 TA755 - Rigidiplem for treating sonal muscular atmorby. 16/12/2021 NO Condition not treated at CWH and WMUH site. TA753 - Cenobamate for treating focal onset seizures in epilepsy. 15/12/2021 TA753 - Cenobamate for treating focal onset seizures in epilepsy. 15/12/2021 TA753 - Deplumab for treating active autoantibody-positive systemic lupus erythematous. 15/12/2021 TA753 - Deplumab for treating active autoantibody-positive systemic lupus erythematous. 15/12/2021 TA753 - Deplumab for treating active autoantibody-positive systemic lupus erythematous. 15/12/2021 TA753 - Deplumab for treating active autoantibody-positive systemic lupus erythematous. 15/12/2021 TA753 - Deplumab for treating active autoantibody-positive systemic lupus erythematous. 15/12/2021 NO Condition on treated at CWH and WMUH site. Not applicable to CWF T. Condition on treated at CWH and WMUH site. Not applicable to CWF T. Condition on treated at CWH and WMUH site. Not applicable to CWF T. Condition on treated at CWH and WMUH site. Not applicable to CWF T. No Terminated appraisal. 16/12/2021 NO Terminated appraisal. 16/12/2021 NO Terminated appraisal. 16/12/2021 NO Terminated appraisal. 16/12/2021 NO Condition on treated at CWH and WMUH site. 16/12/2021 NO Condition on treated at CWH and WMUH site. 16/12/2021 NO Terminated appraisal. 16/12/2021 NO Condition on treated at CWH and WMUH site. 16/12/2021 NO Terminated appraisal. 16/12/2021 NO Terminated appraisal. 16/12/2021 NO Condition on treated at CWH and WMUH site. 16/12/2021 NO Condition on treated at CWH and WMUH site. 16/12/2021 NO Condition on treated at CWH and WMUH site. NO Septimate to CWF T. Condition on treated at CWH and WMUH site. NO Septimate to CWF T. Condition on treated at CWH and WMUH site. NO Condition on treated at CWH and WMUH site. 16/12/2021 NO Con			No	
TA755 - Bisdolam for treating spinal muscular atrophy 16/12/2021 No No Not applicable to CWFT- Condition not treated at CWH and WMUH site 17A754 - Mosemulizumab for previously treated mycosis funesides and Sétany syndrome 15/12/2021 TA752 - Seliminab for treating focal onset seizures in epileoxy 15/12/2021 No No Not applicable to CWFT- Condition not treated at CWH and WMUH site TA752 - Deliminab for treating active automithody-positive systemic lupus enrhemators 16/12/2021 No No Not applicable to CWFT- Condition not treated at CWH and WMUH site TA752 - Deliminab for treating severe asthma with type 2 inflammation 16/12/2021 No No Not applicable to CWFT- Condition not treated at CWH and WMUH site TA753 - Displantible for manifering observed in previous in non-dystrophic myotoxic disorders 16/12/2021 No Terminated appraisal 25/01/2022 No Terminated appraisal 16/12/2021 No Terminated appraisal 16/12/2021 No Terminated appraisal 16/12/2021 No Terminated appraisal 16/12/2021 No Condition not treated at CWH and WMUH site 16/12/2021 No Not applicable to CWFT- Condition not readed at CWH and WMUH site 16/12/2021 No Not applicable to CWFT- Condition not readed at CWH and WMUH site 16/12/2021 No Not applicable to CWFT- Condition not readed at CWH and WMUH site 16/12/2021 No Not applicable to CWFT- Not applicable to CWFT- Not performed a proprietal at CWH and WMUH site 16/12/2021 No No Not applicable to CWFT- Not performed at CWH and WMUH site 16/12/2021 No No Not applicable to CWFT- Not performed at CWH and WMUH site 16/12/2021 No No Not applicable to CWFT- Not performed at CWH and WMUH site 16/12/2021 No No Not applicable to CWFT- Not performed at CWH and WMUH site 16/12/2021 No No Not applicable to CWFT- Not performed at CWH and WMUH site 16/12/2021 No No Not applicable to CWFT- Not performed at CWH and WMUH site 16/12/2021 No No Not applicable to CWFT- Not performed at CWH and WMUH site 16/12/2021 No No applicable to CWFT- Not performed at			Yes	
TA754 - Mogamulizumab for previously treated mycosis fungicides and Sérary syndrome 15/12/2021 No Condition not treated at CWH and WMUH site TA753 - Cenobamate for treating focal onset seizures in epilepsy TA753 - Cenobamate for treating focal onset seizures in epilepsy TA753 - Dupliumab for treating active automitobody-positive systemic lupus erythematosus TA751 - Dupliumab for treating severe asthma with type 2 inflammation No 15/12/2021 No No 15 applicable to CWFT - Condition not treated at CWH and WMUH site TA753 - Dupliumab for treating severe asthma with type 2 inflammation No 15/12/2021 No 16 Terminated appraisal TA753 - Dupliumab for treating severe asthma with type 2 inflammation No 12/12/2021 No Terminated appraisal TA749 - Inactive for managing obesity in people aced 12 to 17 vests I forminated appraisal TA749 - Inactive for managing obesity in people aced 12 to 17 vests I forminated appraisal TA749 - Inactive for managing obesity in people aced 12 to 17 vests I forminated appraisal TA749 - Inactive for managing obesity in people aced 12 to 17 vests I forminated appraisal TA749 - Inactive for managing obesity in people aced 12 to 17 vests I forminated appraisal TA749 - Inactive for managing obesity in people aced 12 to 17 vests I forminated appraisal TA749 - Inactive for treating the symptoms of myotonia in non-divistrophic myotonic disorders TA748 - Mentaletine for treating progressive fibrosing interstital lung diseases TA746 - Nivolumab for adjuvant treatment of esocied occophageal or assity occophageal TA746 - Nivolumab for adjuvant treatment of esocied occophageal or assity occophageal TA741 - Nivolumab for preventing sickle cell crises in sickle cell disease TA742 - Seleparatinib for treating moderate theumatoid arthritis TA743 - Seleparatinib for treating advanced for this such associated accompanies of treating advanced to this such associated accompanies of treating advanced to this provide provide accompanies of treating advanced to the provide accompanies of tre			Yes	Not applicable to CWFT -
TA752 - Benerating for treating focal conset seizures in epileoxy 15/12/2021			No	Condition not treated at CWH and WMUH site
TA752 - Belimumab for treating active autoantibody-positive systemic lupus erythematosus 15/12/2021 NO Not applicable to CWFT - Condition not treated at CWH and WMUH site Not applicable to CWFT - Condition not treated at CWH and WMUH site Not applicable to CWFT - Condition not treated at CWH and WMUH site Not applicable to CWFT - Condition not treated at CWH and WMUH site No Terminated appraisal No Terminated at CWH and WMUH site No Not applicable to CWFT - Condition not treated at CWH and WMUH site No TA747 - Nintedanib for treating progressive fibrosing interstitial lung diseases TA746 - Nivolumab for adius and treatment of rescried desconhase allowed sort sissue sarroma. 10/11/2021 No TA745 - Nintedanib for treating advanced soft tissue sarroma. 10/11/2021 TA744 - Upadactinib for treating advanced soft tissue sarroma. 10/11/2021 TA744 - Upadactinib for treating moderate rheumatoid anthritis 10/11/2021 TA743 - Citraniirumab for preventing sikkle cell crises in sikkle cell disease 33/11/2021 No Terminated appraisal No Terminated appraisal No Terminated appraisal No Terminated appraisal TA741 - Lipadactinib for treating advanced soft tissue sarroma. 10/11/2021 Yes TA743 - Citraniirumab for preventing sikkle cell crises in sikkle cell disease 33/11/2021 No No tapplicable to CWFT - Condition not treated at CWH and WMUH site TA744 - Selecratinib for treating advanced Thrividid cancer with RET alterations No No tapplicable to CWFT - Condition not treated at CWH and WMUH site TA744 - Selecratinib for treating advanced organization therapy for treating high-risk hormone- relabsid non-metastalic prostate cancer TA745 - Nouthernia for untreat			No	1
TA751 - Dupilumab for treating severe asthma with type 2 inflammation TA751 - Dupilumab for treating severe asthma with type 2 inflammation O8/12/2021 NO TA750 - Olipasith for maintenance treatment of BRCA mutation-positive metastatic pancreatic. Cancer after relations based rhemotheranu / Terminated appraisal TA749 - Lirashidde for managing obesity in people aged 12 to 17 years (Terminated appraisal) Z5/01/2022 NO Terminated appraisal A748 - Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders TA747 - Nintedanib for treating progressive fibrosing interstitial lung diseases TA746 - Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal Jonition cancer TA746 - Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal Jonition cancer TA744 - Upadactinib for treating advanced soft tissue sarroma TA744 - Upadactinib for treating moderate rheumatoid arthritis TA744 - Upadactinib for treating moderate rheumatoid arthritis TA742 - Selperatinib for treating advanced soft tissue sarroma TA744 - Apalutamide with androgen deprivation therapy for treating his-risk hormone-sensitive metastatic prostate cancer TA743 - Apalutamide with androgen deprivation therapy for treating his-risk hormone-sensitive metastatic prostate cancer TA743 - Berotralstat for preventing recurrent attacks of hereditary angloedema A737 - Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced according to the head and calculated and MMUH site of the head and calculated and myotogen deprivation therapy for treating high-risk hormone-sensitive advanced copyrimidine-based chemotherapy for untreated and advanced according to treated at CWH and WMUH site TA743 - Berotralstat for preventing recurrent attacks of hereditary angloedema A737 - Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated and advanced descordageal and carried and myould site of the head and calculated and myould site of	TA753 - Cenobamate for treating focal onset seizures in epilepsy	15/12/2021	Yes	
TA750 - Olaparith for maintenance treatment of BRCA mutation-positive metastatic pancreatic, 208/12/2021 No Terminated appraisal (25/01/2022 No Terminated appraisal) (25/01/2022 No Terminated appr			No	Condition not treated at CWH and WMUH site
TA749 - Ling lutide for managing obesity in people aged 12 to 17 years (Terminated appraisal) TA749 - Ling lutide for managing obesity in people aged 12 to 17 years (Terminated appraisal) TA748 - Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders TA748 - Nintedanib for treating progressive fibrosing interstitial lung diseases 17/11/2021 No Condition not treated at CWH and WMUH site Not applicable to CWFT - Condition not treated at CWH and MWUH site Not applicable to CWFT - Condition not treated at CWH and WMUH site Not applicable to CWFT - Condition not treated at CWH and WMUH site No TA745 - NBTXR-3 for treating advanced soft tissue sarcoma 10/11/2021 No TA744 - Upadacitinib for treating moderate rheumatoid arthritis 10/11/2021 Yes TA743 - Crizanlizumab for preventing sickle cell crises in sickle cell disease 37/11/2021 No No No No No No No No No N	TA751 - Dupilumab for treating severe asthma with type 2 inflammation	08/12/2021	No	**
A748 - Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders of 1/12/2021 No No Condition not treated at CWH and WMUH site Not applicable to CWFT - Condition not treated at CWH and WMUH site Not applicable to CWFT - Condition not treated at CWH and WMUH site Not applicable to CWFT - Condition on treated at CWH and WMUH site Not applicable to CWFT - Condition not treated at CWH and WMUH site Not applicable to CWFT - Condition not treated at CWH and WMUH site Not applicable to CWFT - Condition not treated at CWH and WMUH site Not applicable to CWFT - Condition not treated at CWH and WMUH site Not applicable to CWFT - Condition not treated at CWH and WMUH site Not applicable to CWFT - Condition not treated at CWH and WMUH site Not applicable to CWFT - Condition not treated at CWH and WMUH site Not applicable to CWFT - Condition not treated at CWH and WMUH site Not applicable to CWFT - Condition not treated at CWH and WMUH site Not applicable to CWFT - Condition not treated at CWH and WMUH site Not applicable to CWFT - Condition not treated at CWH and WMUH site Not applicable to CWFT - Condition not treated at CWH and WMUH site Not applicable to CWFT - Condition not treated at CWH and WMUH site Not applicable to CWFT - Condition not treated at CWH and WMUH site Not applicable to CWFT - Condition not treated at CWH and WMUH site Not applicable to CWFT - Condition not treated at CWH and WMUH site Not applicable to CWFT - Condition not treated at CWH and WMUH site Not applicable to CWFT - Condition not treated at CWH and WMUH site Not applicable to CWFT - Condition not treated at CWH and WMUH site Not applicable to CWFT - Condition not treated at CWH and WMUH site Not applicable to CWFT - Condition not treated at CWH and WMUH site Not applicable to CWFT - Condition not treated at CWH and WMUH site Not applicable to CWFT - Condition not treated at CWH and WMUH site Not applicable to CWFT - Condition not treated at CWH and WMUH site Not applicable to CWFT - Condition not treated at CWH an	cancer after platinum-based chemotherapy (Terminated appraisal)		No	Terminated appraisal
TA747 - Nintedanib for treating progressive fibrosing interstitial lung diseases TA746 - Nivolumab for adjuvant treating progressive fibrosing interstitial lung diseases TA746 - Nivolumab for adjuvant treating of resected desophageal or gastro-desophageal Intrinsical cancer TA745 - NBTXR-3 for treating advanced soft tissue sarroma TA745 - NBTXR-3 for treating advanced soft districts and soft districts an	TA749 - Liraglutide for managing obesity in people aged 12 to 17 years (Terminated appraisal)		No	
TA747 - Nintedanib for treating progressive fibrosing interstitial lung diseases TA746 - Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal unction cancer TA746 - Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal unction cancer TA745 - NBTXR-3 for treating advanced soft tissue sarcoma TA744 - Upadacitinib for treating moderate rheumatoid arthritis TA744 - Upadacitinib for treating moderate rheumatoid arthritis TA743 - Crizanlizumab for preventing sickle cell crises in sickle cell disease TA742 - Selpercatinib for treating advanced Thyroid cancer with RET alterations TA744 - Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer TA740 - Apalutamide with androgen deprivation therapy for treating high-risk hormone-gased non-metastatic prostate cancer TA740 - Apalutamide with androgen deprivation therapy for treating high-risk hormone-gased non-metastatic prostate cancer TA743 - Benotralstat for preventing recurrent attacks of hereditary angloedema TA738 - Benotralstat for preventing recurrent attacks of hereditary angloedema TA737 - Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated at CWH and WMUH site No TA745 - Nivolumab for treating advanced accompany for untreated at CWH and WMUH site No TA736 - Nivolumab for treating accompany for the plant and representating recurrent or expension and the best and advanced ecophageal and gastro-oesophageal and gastro-oesophag	TA748 - Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders		No	Condition not treated at CWH and WMUH site
TA746 - Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal In/11/2021 No Ta745 - NBTXR-3 for treating advanced soft tissue sarcoma. In/11/2021 In/11/2021		17/11/2021	No	Not applicable to CWFT - Condition not treated at CWH and WMUH site
TA744 - Upadacitinib for treating moderate rheumatoid arthritis TA744 - Upadacitinib for treating moderate rheumatoid arthritis TA743 - Crizaniizumab for preventing sickle cell crises in sickle cell disease O3/11/2021 No No Not applicable to CWFT - Condition not treated at CWH and WMUH site Not applicable to CWFT - Condition not treated at CWH and WMUH site TA742 - Selpercatinib for treating advanced Thyroid cancer with RET alterations TA741 - Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer TA740 - Apalutamide with androgen deprivation therapy for treating high-risk hormone- relapsed non-metastatic prostate cancer TA740 - Apalutamide with androgen deprivation therapy for treating high-risk hormone- relapsed non-metastatic prostate cancer TA739 - Atezolizumab for untreated PD-11-positive advanced urothelial cancer when cisplatinis unsuitable TA738 - Berotralistat for preventing recurrent attacks of hereditary angioedema TA737 - Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal langton cancery for untreated advanced oesophageal and gastro-oesophageal incrition cancery for untreated at CWH and WMUH site TA736 - Nivolumah for treating recurrent or metastatic synamus cell carcinoma of the head and		17/11/2021	No	Not applicable to CWFT -
TA743 - Crizanlizumab for preventing sickle cell crises in sickle cell disease TA742 - Selpercatinib for treating advanced Thyroid cancer with RET alterations TA742 - Selpercatinib for treating advanced Thyroid cancer with RET alterations TA741 - Apalutamide with androgen deprivation therapy for treating hormone-sensitive. metastatic prostate cancer TA740 - Apalutamide with androgen deprivation therapy for treating high-risk hormone- relapsed non-metastatic prostate cancer TA740 - Apalutamide with androgen deprivation therapy for treating high-risk hormone- relapsed non-metastatic prostate cancer TA740 - Apalutamide with androgen deprivation therapy for treating high-risk hormone- relapsed non-metastatic prostate cancer TA740 - Apalutamide with androgen deprivation therapy for treating high-risk hormone- relapsed non-metastatic prostate cancer TA740 - Apalutamide with androgen deprivation therapy for treating high-risk hormone- relapsed non-metastatic prostate cancer TA739 - Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable TA738 - Berotralstat for preventing recurrent attacks of hereditary angloedema TA737 - Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal incition cancer TA736 - Nivorable for treating recurrent or metastatic squareus cell carcinoma of the head and target on treated at CWH and WMUH site TA736 - Nivorable for treating recurrent or metastatic squareus cell carcinoma of the head and target on the part of the part of the part of the part of the par		10/11/2021	No	
TA742 - Selpercatinib for treating advanced Thyroid cancer with RET alterations TA742 - Selpercatinib for treating advanced Thyroid cancer with RET alterations TA741 - Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer TA740 - Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer TA740 - Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer TA740 - Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer TA740 - Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer TA740 - Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer TA740 - Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer TA740 - Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer TA740 - Apalutamide with platinum- and fluoropyrimidine-based chemotherapy for untreated at CWH and WMUH site TA748 - New June 10 - June 1	TA744 - Upadacitinib for treating moderate rheumatoid arthritis	10/11/2021	Yes	
TA742 - Selpercatinib for treating advanced Thyroid cancer with RET alterations IA741 - Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer IA740 - Apalutamide with androgen deprivation therapy for treating high-risk hormone-sensitive metastatic prostate cancer IA740 - Apalutamide with androgen deprivation therapy for treating high-risk hormone-gelapsed non-metastatic prostate cancer IA740 - Apalutamide with androgen deprivation therapy for treating high-risk hormone-gelapsed non-metastatic prostate cancer IA740 - Apalutamide with particular deviation treated and prostate cancer IA740 - Apalutamide with particular deviation treated and prostate cancer IA740 - Apalutamide with particular deviation treated and prostate cancer IA740 - Apalutamide with particular deviation treated and pastor occupance of the beard and pastor occupance o	TA743 - Crizanlizumab for preventing sickle cell crises in sickle cell disease	03/11/2021	No	Condition not treated at CWH and WMUH site
TA741 - Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer TA740 - Apalutamide with androgen deprivation therapy for treating high-risk hormone-gelapsed non-metastatic prostate cancer TA739 - Atezolizumab for untreated PD-11-positive advanced urothelial cancer when cisplatin is unsuitable TA738 - Berotralstat for preventing recurrent attacks of hereditary angioedema TA737 - Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer A736 - Nivolumab for treating recurrent or metastatic group of the head and the platinum and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal sinction cancer A736 - Nivolumab for treating recurrent or metastatic squarous cell carring more of the head and the platinum and fluoropyrimidine-based platinum and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal sinction cancer A736 - Nivolumab for treating recurrent or metastatic squarous cell carring more of the head and the platinum and fluoropyrimidine-based platinum and fluoropyrimidine-based chemotherapy for untreated at CWH and WMUH site A737 - Pembrolizumab for treating recurrent or metastatic squarous cell carring more of the head and the platinum and fluoropyrimidine-based platinum and fluoropyrimidine-based platinum and fluoropyrimidine-based chemotherapy for untreated at CWH and WMUH site A736 - Nivolumab for treating recurrent or metastatic squarous cell carring more of the head and the platinum and fluoropyrimidine-based chemotherapy for untreated at CWH and WMUH site		03/11/2021	No	Not applicable to CWFT -
TA740 - Apalutamide with androgen deprivation therapy for treating high-risk hormone- relapsed non-metastatic prostate cancer TA739 - Atezolizumab for untreated PD-11-positive advanced urothelial cancer when cisplatin is unsuitable TA738 - Berotralstat for preventing recurrent attacks of hereditary angioedema Z0/10/2021 No Not applicable to CWFT - Condition not treated at CWH and WMUH site No advanced oesophageal and gastro-oesophageal junction cancer A736 - Nivolumab for treating recurrent or metastatic squarous cell carcinoma of the head and Z0/10/2021		28/10/2021	Yes	
TA739 - Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable TA738 - Berotralstat for preventing recurrent attacks of hereditary angioedema TA737 - Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated at CWH and WMUH site No No applicable to CWFT - Condition not treated at CWH and WMUH site No Condition not treated at CWH and WMUH site No Condition not treated at CWH and WMUH site A736 - Nivolumab for treating recurrent or metastatic squarous cell carringon of the head and condition in the plant of treated at CWH and WMUH site	TA740 - Apalutamide with androgen deprivation therapy for treating high-risk hormone-	28/10/2021	Yes	
TA738 - Berotralstat for preventing recurrent attacks of hereditary angioedema 20/10/2021 No Not applicable to CWFT - Condition not treated at CWH and WMUH site Not applicable to CWFT - Condition not treated at CWH and WMUH site No No Condition not treated at CWH and WMUH site No Condition not treated at CWH and WMUH site No No No applicable to CWFT - Condition not treated at CWH and WMUH site 20/10/2021 No No No applicable to CWFT - Condition not treated at CWH and WMUH site 20/10/2021	TA739 - Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is	27/10/2021	Yes	
advanced oesophageal and gastro-oesophageal junction cancer No Condition not treated at CWH and WMUH site 1A736 - Nivolumah for treating recurrent or metastatic squamous cell carringma of the head and 20/10/2021 Not applicable to CWFT -		20/10/2021	No	1
TA736 - Nivolumah for treating recurrent or metastatic squamous cell carrinoma of the head and 20/10/2021		20/10/2021	No	1.1
neck after platinum-based chemotherapy No Condition not treated at CWH and WMUH site	TA736 - Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and	20/10/2021	No	Not applicable to CWFT -

Yes No	Terminated appraisal Terminated appraisal Terminated appraisal Terminated appraisal Not applicable to CWFT - Condition not treated at CWH and WMUH site Not applicable to CWFT - Condition not treated at CWH and WMUH site Terminated appraisal Terminated appraisal Not recommended Not applicable to CWFT - Condition not treated at CWH and WMUH site
Yes No	Terminated appraisal Terminated appraisal Not applicable to CWFT - Condition not treated at CWH and WMUH site Not applicable to CWFT - Condition not treated at CWH and WMUH site Terminated appraisal Terminated appraisal Not recommended Not applicable to CWFT - Condition not treated at CWH and WMUH site
No Yes No No No	Terminated appraisal Terminated appraisal Not applicable to CWFT - Condition not treated at CWH and WMUH site Not applicable to CWFT - Condition not treated at CWH and WMUH site Terminated appraisal Terminated appraisal Not recommended Not applicable to CWFT - Condition not treated at CWH and WMUH site
No No No No No No No Yes No No No	Terminated appraisal Terminated appraisal Not applicable to CWFT - Condition not treated at CWH and WMUH site Not applicable to CWFT - Condition not treated at CWH and WMUH site Terminated appraisal Terminated appraisal Not recommended Not applicable to CWFT - Condition not treated at CWH and WMUH site
No No No No No Yes No No No Yes	Terminated appraisal Not applicable to CWFT - Condition not treated at CWH and WMUH site Not applicable to CWFT - Condition not treated at CWH and WMUH site Terminated appraisal Terminated appraisal Not recommended Not applicable to CWFT - Condition not treated at CWH and WMUH site
No No No No Yes No Yes No No	Not applicable to CWFT - Condition not treated at CWH and WMUH site Not applicable to CWFT - Condition not treated at CWH and WMUH site Terminated appraisal Terminated appraisal Not recommended Not applicable to CWFT - Condition not treated at CWH and WMUH site
No No No Yes No Yes No No	Condition not treated at CWH and WMUH site Not applicable to CWFT - Condition not treated at CWH and WMUH site Terminated appraisal Terminated appraisal Not recommended Not applicable to CWFT - Condition not treated at CWH and WMUH site
No No Yes No Yes No No No	Condition not treated at CWH and WMUH site Terminated appraisal Terminated appraisal Not recommended Not applicable to CWFT - Condition not treated at CWH and WMUH site
No Yes No Yes No No	Not recommended Not applicable to CWFT - Condition not treated at CWH and WMUH site
Yes No Yes No No	Not recommended Not applicable to CWFT - Condition not treated at CWH and WMUH site
No Yes No	Not applicable to CWFT - Condition not treated at CWH and WMUH site
Yes No No	Not applicable to CWFT - Condition not treated at CWH and WMUH site
No No	Condition not treated at CWH and WMUH site
No	Condition not treated at CWH and WMUH site
	Not recommended
No	
	Not applicable to CWFT - Condition not treated at CWH and WMUH site
Vec	Condition not dealed at CWH and WIMOH Site
Yes	
Yes	
No	Terminated appraisal
Yes	
Yes	
No	Terminated appraisal
Ves	
Yes	
No	Not applicable to CWFT - Not a commissioned site
Yes	
Yes	
No	Not applicable to CWFT - Condition not treated at CWH and WMUH site
No	Not recommended
Yes	
Yes	
No	Terminated appraisal
Yes	
No	Not applicable to CWFT - Not a commissioned site
Yes	
No	Not recommended
Yes	
Yes	
	Yes Yes No Yes Yes Yes Yes No Yes Yes No No No No Yes No

TA693 - Olaparib plus bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer	28/04/2021	No	Not applicable to CWFT - Condition not treated at CWH and WMUH site
TA692 - Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy.	28/04/2021	No	Not recommended
TA691 - Avelumab for untreated metastatic Merkel cell carcinoma.	21/04/2021	Yes	
TA690 - Teduglutide for treating short bowel syndrome (terminated appraisal)	21/04/2021	No	Terminated appraisal